共 302 条
[1]
Waks AG(2019)Breast Cancer Treatment: a review JAMA 321 288-300
[2]
Winer EP(2020)Overcoming endocrine resistance in breast Cancer Cancer Cell 37 496-513
[3]
Hanker AB(2016)Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast Cancer: a review of preclinical and clinical data Clin Breast Cancer 16 8-17
[4]
Sudhan DR(2022)ABC6 Consensus: Assessment by a group of german experts Breast Care (Basel) 17 90-100
[5]
Arteaga CL(2020)Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Cancer Network: JNCCN 18 452-78
[6]
Vidula N(2016)Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 17 425-39
[7]
Rugo HS(2019)Palbociclib Plus Letrozole as First-Line therapy in postmenopausal asian women with metastatic breast Cancer: results from the Phase III, Randomized PALOMA-2 study J global Oncol 5 1-19
[8]
Luftner D(2016)Efficacy and safety of Palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 Breast cancer research: BCR 18 67-303
[9]
Fasching PA(2017)PALOMA-3: phase III trial of Fulvestrant with or without Palbociclib in Premenopausal and Postmenopausal Women with hormone Receptor-Positive, human epidermal growth factor receptor 2-Negative metastatic breast Cancer that progressed on prior endocrine therapy-safety and efficacy in asian patients J global Oncol 3 289-7
[10]
Haidinger R(2019)Real-world effectiveness of Palbociclib Versus Clinical Trial results in patients with Advanced/Metastatic breast Cancer that progressed on previous endocrine therapy Breast Cancer (Auckl) 13 1178223418823238-40